Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Support MFO
Donate through PayPal
Any Bubble In Biotech Would Hit Small Caps Hardest
FYI: Owners of biotech stocks know better than anyone that the sector has been a serious winner since 2011. This cohort also know the flip side, that “when performance turns south, it’s usually fast and furious.” Those are the words of Christina Giannini, Bank of America Merrill Lynch’s small-cap strategist, who ponders in a report this morning whether biotech stocks are in a bubble. Regards, Ted http://blogs.barrons.com/focusonfunds/2015/07/31/any-bubble-in-biotech-would-hit-small-caps-hardest/tab/print/
